Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Patel SP, Othus M, Chae YK, Kurzrock R, et al. Clin Cancer Res 2020;26:2434.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Patel SP, Othus M, Chae YK, Kurzrock R, et al. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res 2020;26:2434.
PMID: 32414761